Results 51 to 60 of about 4,918,610 (234)
COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS
Рациональная фармакотерапия в кардиологии, 2015 Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed ...
V. A. Sulimov +2 more
doaj +3 more sources
Changes in Internal Structure and Dynamics upon Binding Stabilise the Nematode Anticoagulant NAPc2
BiomoleculesAbnormal blood coagulation is a major health problem and natural anticoagulants from blood-feeding organisms have been investigated as novel therapeutics.
Elaine Woodward, Brendan M. Duggan
doaj +1 more source
Атеротромбоз, 2020 Introduction. The direct oral anticoagulants (DOC) therapy does not require alaboratory control; however, it may be required to determine the anticoagulationlevel to choose a treatment strategy if alarge bleeding is developing or emergency surgery is ...
E. V. Titaeva, A. B. Dobrovolsky
doaj +1 more source
Corporate Social Responsibility and Environmental Management, EarlyView.ABSTRACT Companies increasingly claim to adopt artificial intelligence (AI) not only for economic but also for ecological and social purposes. However, in light of rising greenwashing, bluewashing, and ethics washing, the impact of the communicated rationale on employees' initial attitude toward AI introduction remains unclear.
Marco Baumgartner +3 more
wiley +1 more source
Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data?
Advances in Hematology, 2011 The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and treatment of VTE in cancer patients is imperative.
Ali Zalpour +4 more
doaj +1 more source
New oral anticoagulants and cardiac safety: do we have a problem?
Медицинский совет, 2018 This analytic review provides the information about frequency of myocardial infarction in patients, treated with direct oral anticoagulants in randomized clinical trials and retrospective cohort studies.
E. M. Nifontov
doaj +1 more source
Pharmacology Research & Perspectives, 2022 Apixaban is a factor Xa (FXa) inhibitor and standard‐of‐care anticoagulant with FXa Ki and plasma protein binding (free fraction) averages 0.08 nM and 0.13 in humans and 0.16 nM and 0.37 in rabbits, respectively. Apixaban at the approved dose of 5 mg BID
Pancras C. Wong, Earl Crain
doaj +1 more source
Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation
, 2016 Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. The molecule is a recombinant protein analog of factor Xa that binds to Factor Xa inhibitors and antithrombin:LMWH complex but does not trigger prothrombotic activity.
Dombrowski, KE +3 more
core +1 more source
The role of factor Xa inhibitors in venous thromboembolism treatment [PDF]
, 2015 Katherine P Cabral,1 Jack E Ansell2 1Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2Hofstra-North Shore/LIJ School of Medicine, Hempstead, NY, USA Abstract: Three factor Xa inhibitors have been studied
Ansell, J. E. +3 more
core +1 more source
The Role of Factor Xa-Independent Pathway and Anticoagulant Therapies in Cancer-Related Stroke
, 2021 Background: The optimal strategy for stroke prevention in cancer patients is unknown. We compared the underlying mechanisms of coagulopathy and the effects of anticoagulants in patients with active cancer and atrial fibrillation (AF).
Hee-Jin Kim +9 more
core +1 more source